Therapeutic Approaches in Lowering Albuminuria: Travels Along the Renin-Angiotensin-Aldosterone-System Pathway

Advances in Chronic Kidney Disease

Volumn 18, Issue 4, 2011, Pages 290-299

  Lambers Heerspink, Hiddo J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Albuminuria; Aldosterone; Angiotensin converting enzyme; Angiotensin receptor blocker; Cardiovascular disease; Microalbuminuria; Nephropathy; Renin Angiotensin Aldosterone System; Sodium

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CANDESARTAN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; PERINDOPRIL; PLACEBO; RAMIPRIL; REMIKIREN; RENIN INHIBITOR; SODIUM; TELMISARTAN; VALSARTAN; VITAMIN D RECEPTOR;

ALBUMINURIA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETES MELLITUS; DIET RESTRICTION; DIURETIC THERAPY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SODIUM RESTRICTION; SODIUM URINE LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ALBUMINURIA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; RECEPTORS, MINERALOCORTICOID; RENAL INSUFFICIENCY, CHRONIC; RENIN; RENIN-ANGIOTENSIN SYSTEM; SODIUM, DIETARY; TREATMENT OUTCOME;

EID: 79960479677     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2011.04.001     Document Type: Review

References (56)

1. Ruggenenti P., Perna A., Gherardi G., et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999, 354:359-364.
2. Bjorck S., Mulec H., Johnsen S.A., Nyberg G., Aurell M. Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. BMJ 1990, 300:904-907.
3. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456-1462. The Collaborative Study Group.
4. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
5. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
6. Rossing P., Hommel E., Smidt U.M., Parving H.H. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994, 37:511-516.
7. Apperloo A.J., de Zeeuw D., de Jong P.E. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int Suppl 1994, 45:S174-S178.
8. de Zeeuw D., Remuzzi G., Parving H.H., et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004, 65:2309-2320.
9. Atkins R.C., Briganti E.M., Lewis J.B., et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005, 45:281-287.
10. de Zeeuw D., Remuzzi G., Parving H.H., et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004, 110:921-927.
11. Patel A., MacMahon S., Chalmers J., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829-840.
12. Maschio G., Alberti D., Janin G., et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996, 334:939-945.
13. Hou F.F., Zhang X., Zhang G.H., et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006, 354:131-140.
14. Marre M., Lievre M., Chatellier G., Mann J.F., Passa P., Menard J. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004, 328:495.
15. Yusuf S., Teo K.K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559.
16. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349:1857-1863. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
17. de Zeeuw D., Lambers Heerspink H.J., Gansevoort R.T., Bakker S.J.L. How to improve renal outcome in diabetes and hypertension - the importance of early screening for and treatment of microalbuminuria. Eur Nephrol 2009, 3:13-15.
18. Heerspink H.L., de Zeeuw D. Pharmacology: defining the optimal dose of a new drug: a crucial decision. Nat Rev Nephrol 2009, 5:498-500.
19. Rossing K., Schjoedt K.J., Jensen B.R., Boomsma F., Parving H.H. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005, 68:1190-1198.
20. Schjoedt K.J., Astrup A.S., Persson F., et al. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial. Diabetologia 2009, 52:46-49.
21. Weir M.R., Hollenberg N.K., Zappe D.H., et al. Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. J Hypertens 2010, 28:186-193.
22. Burgess E., Muirhead N., Rene de Cotret P., Chiu A., Pichette V., Tobe S. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009, 20:893-900.
23. Bos H., Andersen S., Rossing P., et al. Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney Int Suppl 2000, 75:S32-S37.
24. Kunz R., Friedrich C., Wolbers M., Mann J.F. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008, 148:30-48.
25. Laverman G.D., Navis G., Henning R.H., de Jong P.E., de Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002, 62:1020-1025.
26. Laverman G.D., de Zeeuw D., Navis G. Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy?. J Renin Angiotensin Aldosterone Syst 2002, 3:205-213.
27. Mann J.F., Schmieder R.E., McQueen M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553.
28. Jafar T.H., Stark P.C., Schmid C.H., et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001, 60:1131-1140.
29. Lambers Heerspink H.J., de Zeeuw D. Dual RAS therapy not on target, but fully alive. Nephron Clin Pract 2010, 116:c137-c142.
30. Maione A., Nicolucci A., Craig J.C., et al. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial. J Nephrol 2007, 20:646-655.
31. Fried L.F., Duckworth W., Zhang J.H., et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009, 4:361-368.
32. Schmieder R.E., Mann J.F., Schumacher H., et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. Journal of Hypertension 2010, 28:e602.
33. Skeggs L.T., Kahn J.R., Lentz K., Shumway N.P. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957, 106:439-453.
34. Lambers Heerspink H.J., Perkovic V., de Zeeuw D. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review. J Hypertens 2009, 27:2321-2331.
35. Persson F., Rossing P., Schjoedt K.J., et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008, 73:1419-1425.
36. Persson F., Rossing P., Reinhard H., et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009, 32:1873-1879.
37. Parving H.H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433-2446.
38. Andersen K., Weinberger M.H., Constance C.M., et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. J Renin Angiotensin Aldosterone Syst 2009, 10:157-167.
39. Parving H.H., Brenner B.M., McMurray J.J., de Zeeuw D., Haffner S.M., Solomon S.D., et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009, 24:1663-1671.
40. Rossing K., Schjoedt K.J., Smidt U.M., Boomsma F., Parving H.H. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005, 28:2106-2112.
41. Chrysostomou A., Pedagogos E., MacGregor L., Becker G.J. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006, 1:256-262.
42. Mehdi U.F., Adams-Huet B., Raskin P., Vega G.L., Toto R.D. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009, 20:2641-2650.
43. Epstein M., Williams G.H., Weinberger M., et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006, 1:940-951.
44. Miao Y., Dobre D., Heerspink H.J., et al. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia 2011, 54:44-50.
45. de Gasparo M., Whitebread S.E., Preiswerk G., Jeunemaitre X., Corvol P., Menard J. Antialdosterones: incidence and prevention of sexual side effects. J Steroid Biochem 1989, 32:223-227.
46. Brown R., Quirk J., Kirkpatrick P. Eplerenone. Nat Rev Drug Discov 2003, 2:177-178.
47. Schjoedt K.J., Andersen S., Rossing P., Tarnow L., Parving H.H. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004, 47:1936-1939.
48. Sato A., Hayashi K., Naruse M., Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003, 41:64-68.
49. Houlihan C.A., Allen T.J., Baxter A.L., et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care 2002, 25:663-671.
50. Vedovato M., Lepore G., Coracina A., et al. Effect of sodium intake on blood pressure and albuminuria in type 2 diabetic patients: the role of insulin resistance. Diabetologia 2004, 47:300-303.
51. Ekinci E.I., Thomas G., Thomas D., et al. Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake. Diabetes Care 2009, 32:1398-1403.
52. Heeg J.E., de Jong P.E., van der Hem G.K., de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989, 36:272-279.
53. Buter H., Hemmelder M.H., Navis G., de Jong P.E., de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998, 13:1682-1685.
54. Vogt L., Waanders F., Boomsma F., de Zeeuw D., Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008, 19:999-1007. 0.
55. Lely T.A., Heerspink H.J., Zuurman M., et al. Response to angiotensin-converting enzyme inhibition is selectively blunted by high sodium in angiotensin-converting enzyme DD genotype: evidence for gene-environment interaction in healthy volunteers. J Hypertens 2010, 28:2414-2421.
56. Esnault V.L., Ekhlas A., Nguyen J.M., Moranne O. Diuretic uptitration with half dose combined ACEI + ARB better decrease proteinuria than combined ACEI + ARB uptitration. Nephrol Dial Transplant 2010, 25:2218-2224.